Gene therapy for advanced retinitis pigmentosa
Part of Eyes & vision, Genetic & congenital clinical trials.
This study tests a new gene therapy that may help people with advanced retinitis pigmentosa see better. It uses a modified virus to deliver a light-sensitive protein to the retina, and the trial compares the real treatment to a sham (fake) procedure to check safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between the ages of 6 and 60.
- You must have an advanced form of retinitis pigmentosa, a genetic condition that causes vision loss.
- Your vision in the study eye must be very poor, as defined by the study's threshold.
- Screening tests must show that your retina has enough healthy tissue for the therapy.
- You must be able to understand and sign a consent form (or have a parent/guardian do so).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new gene therapy called UGX202 for people with advanced retinitis pigmentosa, an eye disease that causes vision loss. The goal is to see if it is safe and if it can help improve vision.
This trial tests an investigational gene therapy injection (UGX202) for people with advanced retinitis pigmentosa. The goal is to see if the injection is safe and can help preserve or improve vision in people who still have some memory of seeing.
This trial tests a new peptide therapy for people with retinitis pigmentosa (RP), a genetic eye disease that causes vision loss. The goal is to see if the treatment is safe and can help slow or improve vision loss.
This trial tests a gentle laser treatment (SML) for people with retinitis pigmentosa (RP), an inherited eye disease that slowly causes vision loss. The goal is to see if the laser can help slow or improve vision problems like night blindness and tunnel vision.
This study tests a new gene therapy for people with advanced rod-cone dystrophy, a genetic condition that causes progressive vision loss. The treatment is given as an injection into the eye, and the study aims to see if it is safe and if it can help improve or preserve vision.
This experimental gene therapy (ZM-02) is designed for people with advanced retinitis pigmentosa who have very poor vision (counting fingers or worse). It aims to see if the treatment is safe and can improve vision by replacing a faulty gene in the retina.
Hear when a new Retinitis Pigmentosa (RP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.